AU1796402A - Gene regulation therapy involving ferritin - Google Patents
Gene regulation therapy involving ferritinInfo
- Publication number
- AU1796402A AU1796402A AU1796402A AU1796402A AU1796402A AU 1796402 A AU1796402 A AU 1796402A AU 1796402 A AU1796402 A AU 1796402A AU 1796402 A AU1796402 A AU 1796402A AU 1796402 A AU1796402 A AU 1796402A
- Authority
- AU
- Australia
- Prior art keywords
- ferritin
- gene
- expression
- disease
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 108050000784 Ferritin Proteins 0.000 title 1
- 102000008857 Ferritin Human genes 0.000 title 1
- 238000008416 Ferritin Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 101710099785 Ferritin, heavy subunit Proteins 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024412 Friedreich ataxia Diseases 0.000 abstract 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 abstract 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 abstract 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003855 cell nucleus Anatomy 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000010438 iron metabolism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24500300P | 2000-11-01 | 2000-11-01 | |
| PCT/US2001/044847 WO2002036634A2 (en) | 2000-11-01 | 2001-11-01 | Gene regulation therapy involving ferritin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1796402A true AU1796402A (en) | 2002-05-15 |
Family
ID=22924943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU1796402A Pending AU1796402A (en) | 2000-11-01 | 2001-11-01 | Gene regulation therapy involving ferritin |
| AU2002217964A Ceased AU2002217964B2 (en) | 2000-11-01 | 2001-11-01 | Gene regulation therapy involving ferritin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002217964A Ceased AU2002217964B2 (en) | 2000-11-01 | 2001-11-01 | Gene regulation therapy involving ferritin |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7517669B2 (xx) |
| EP (1) | EP1354032B1 (xx) |
| JP (1) | JP2005512941A (xx) |
| AT (1) | ATE335811T1 (xx) |
| AU (2) | AU1796402A (xx) |
| CA (1) | CA2427629A1 (xx) |
| DE (1) | DE60122211T2 (xx) |
| ES (1) | ES2269506T3 (xx) |
| PT (1) | PT1354032E (xx) |
| WO (1) | WO2002036634A2 (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089521B2 (en) * | 2001-11-01 | 2015-07-28 | Robert H. Broyles | Method for regulating production of hemoglobin beta chains |
| SI1764348T1 (sl) * | 2005-09-16 | 2009-10-31 | Techinsche Universiteit Delft | Postopek za odstranjevanje okso-anionov in kovinskih kationov iz tekočine |
| US8071542B2 (en) * | 2007-01-29 | 2011-12-06 | Chyna, LLC | Use of ferritin to treat iron deficiency disorders |
| WO2008100886A1 (en) * | 2007-02-12 | 2008-08-21 | Auspex Pharmaceuticals, Inc. | Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction |
| CA2719577C (en) * | 2008-03-28 | 2016-11-22 | Chyna Llc | Use of ferritin to treat iron deficiency disorders |
| US10617770B2 (en) * | 2015-04-24 | 2020-04-14 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
| CA3102319A1 (en) | 2018-06-04 | 2019-12-12 | Sidero Bioscience, Llc | Compositions and methods for improvement of iron metabolism and gut microbiome health |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582820A (en) * | 1982-12-23 | 1986-04-15 | Research Corporation | Orally administered biologically active peptides and proteins |
-
2001
- 2001-11-01 DE DE60122211T patent/DE60122211T2/de not_active Expired - Lifetime
- 2001-11-01 PT PT01992721T patent/PT1354032E/pt unknown
- 2001-11-01 EP EP01992721A patent/EP1354032B1/en not_active Expired - Lifetime
- 2001-11-01 AU AU1796402A patent/AU1796402A/xx active Pending
- 2001-11-01 WO PCT/US2001/044847 patent/WO2002036634A2/en active IP Right Grant
- 2001-11-01 AT AT01992721T patent/ATE335811T1/de not_active IP Right Cessation
- 2001-11-01 AU AU2002217964A patent/AU2002217964B2/en not_active Ceased
- 2001-11-01 US US10/003,669 patent/US7517669B2/en not_active Expired - Fee Related
- 2001-11-01 JP JP2002539392A patent/JP2005512941A/ja not_active Withdrawn
- 2001-11-01 CA CA002427629A patent/CA2427629A1/en not_active Abandoned
- 2001-11-01 ES ES01992721T patent/ES2269506T3/es not_active Expired - Lifetime
-
2004
- 2004-04-06 US US10/818,676 patent/US20040186048A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002036634A3 (en) | 2003-07-24 |
| AU2002217964B2 (en) | 2005-11-03 |
| DE60122211T2 (de) | 2007-08-30 |
| WO2002036634A2 (en) | 2002-05-10 |
| ES2269506T3 (es) | 2007-04-01 |
| US7517669B2 (en) | 2009-04-14 |
| EP1354032B1 (en) | 2006-08-09 |
| US20020128183A1 (en) | 2002-09-12 |
| DE60122211D1 (de) | 2006-09-21 |
| ATE335811T1 (de) | 2006-09-15 |
| JP2005512941A (ja) | 2005-05-12 |
| EP1354032A2 (en) | 2003-10-22 |
| US20040186048A1 (en) | 2004-09-23 |
| CA2427629A1 (en) | 2002-05-10 |
| PT1354032E (pt) | 2006-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fuqua | Treatment and outcomes of precocious puberty: an update | |
| AU1796402A (en) | Gene regulation therapy involving ferritin | |
| WO1995027512A3 (en) | Compositions and methods for gene therapy to treat disease | |
| Nieto‐Bona et al. | Orthograde transport and release of insulin‐like growth factor I from the inferior olive to the cerebellum | |
| JUSKO et al. | Partial pharmacodynamic model for the circadian-episodic secretion of cortisol in man | |
| DE60044431D1 (en) | Xenotransplant für zns therapie | |
| NO970312L (no) | Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler | |
| Gold et al. | Basic and Clinical Studies with Corticotropin-Releasing Hormone: Implocations for a Possible Role in Panic Disorder | |
| AP2004003177A0 (en) | Composition and its therapeutic use | |
| CA2116327A1 (en) | Method and compositions for cellular reprogramming | |
| PL353035A1 (en) | Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis | |
| AU2002358346A1 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| Eisenbarth et al. | Inhibition of chondromucoprotein synthesis: an extraneuronal effect of nerve growth factor. | |
| Norström et al. | Effect of suckling and parturition on axonal transport and turnover of neurohypophysial proteins of the rat | |
| Breen et al. | The development of diurnal rhythmicity in fetal suprachiasmatic neurons as demonstrated by fos immunohistochemistry | |
| GB2249312B (en) | Cell growth inhibitors | |
| Campbell et al. | Insulin-like growth factor I stimulates sodium-phosphate cotransport in the rat osteoblastic cell line UMR-106-01 | |
| Vaysse | Somatostatin 14 and 28: Modulation of the action of VIP and related peptides | |
| Rostène | Neurobiological and neuroendocrine roles of VIP: An overview | |
| Bartkó et al. | Blink rate response to haloperidol as possible predictor of therapeutic outcome. | |
| DeLisi | Language and schizophrenia: What do they have to do with speciation? | |
| Flerov et al. | The use of HSP70 for prevention of consequences of unavoidable stress in rats | |
| Myers et al. | Action of anorexigenic peptide injected into the brain: Dissociation of effect on body weight and feeding in the rat | |
| TH11411EX (th) | อีพิธีลินส์ | |
| Ansell et al. | The effect of penicillamine on growth as height in juvenile chronic polyarthritis |